


## CLAIMS

1. A compound of formula I




I

5 or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 being 8-[(2,6-dimethylbenzyl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt.

- 10 3. A process for the preparation of a compound according to claims 1 or 2, comprising the steps of


a) treating a compound of Formula II



II


wherein  $R^1$  represents a  $C_1$ - $C_6$ -alkoxy group or  $-NH_2$ ,

in the presence of an aqueous acid or base, under standard conditions to a compound of Formula III



III

b) reacting the compound of Formula III with a compound of Formula IV




IV

in the presence of a coupling reagent in an inert solvent under standard conditions to give a compound of Formula I.

4. A compound according to claim 1 or 2 for use in therapy.
5. A pharmaceutical formulation containing a compound according to claim 1 or 2 as active ingredient in combination with a pharmaceutically acceptable diluent or carrier.
6. Use of a compound according to claim 1 or 2 for the manufacture of a medicament for the treatment and inhibition of gastric acid related diseases, gastrointestinal inflammatory diseases, symptomatic GERD, erosive esophagitis, peptic ulcer disease, heartburn, regurgitation, acid reflux diseases or nausea.

7. A method of treatment and/or inhibiting gastric acid related diseases, gastrointestinal inflammatory diseases, heartburn, symptomatic GERD, erosive esophagitis, peptic ulcer disease, regurgitation, acid reflux diseases or nausea in human or non-human mammal which comprises administering an effective amount of a compound according to claim 1 or  
5 2, to a human or non-human mammal in need thereof.

8. A compound of Formula III



III